Category - Feature

Feature

Tear Film Innovations readies launch of iLux device for dry eye disease

By Len Zehrs Closely-held Tear Film Innovations plans to formally launch at two upcoming medical conferences its iLux medical device to treat Meibomian gland dysfunction, the leading cause of dry eye disease. The...

April 10, 2018

Feature

Myomo scaling up distribution of MyoPro robotic arm brace

By Len Zehrs Myomo (NYSE American:MYO) is moving from a controlled introduction over the past few years to a scale up sales and distribution of its MyoPro product line of lightweight, non-invasive, powered arm braces to...

April 3, 2018

Feature

Australia tax incentives spurring R&D

By Len Zehrs Australia is riding a wave of R&D, thanks to generous government tax incentives, as well as the quality of contract research and speed of performing clinical trials. The incentives provide businesses...

March 27, 2018

Feature

Vital Therapies pivotal ELAD trial to read out at end of third quarter

By Len Zehrs Vital Therapies (NASDAQ:VTL) expects to report top line data from its ELAD pivotal study, known as VTL-308, in patients with severe alcoholic hepatitis (sAH), an acute form of liver failure, by the end of...

March 20, 2018

Feature

DarioHealth simplifies diabetes with managed care platform

By Len Zehrs DarioHealth’s (NASDAQ:DRIO) diabetes managed care platform covers all facets of the disease, with a blood glucose device coupled directly to a patient’s smartphone to provide 100% data...

March 13, 2018

Feature

liberDi readies first-in-man study of portable dialysis system

By Len Zehrs Closely-held liberDi plans to initiate in the first half of 2018 the first-in-man clinical trial of its Smart Peritoneal Dialysis System, a small, portable and automatic dialysis device, which is designed...

March 6, 2018

Feature

Scientus Pharma considering go-public transaction on heels of financing

By Len Zehrs Closely-held Scientus Pharma hopes to go public in mid-year, possibly through a reverse takeover of a publicly traded shell company, following a successful $15.8-million private equity financing, which...

February 27, 2018

Feature

3DS Telo-HL test aims to personalize cancer treatment

By Len Zehrs 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) has reported positive results from a preliminary analysis of trial data for Telo-HL, its test for Hodgkin’s lymphoma (HL) that is designed to personalize...

February 20, 2018

Feature

Strong scientific rationale for IntelGenx montelukast program

By Len Zehrs IntelGenx (OTCQX:IGXT; TSXV:IGX), which has initiated a proof-of-concept study with its Montelukast VersaFilm in patients with Alzheimer’s disease, using a drug originally approved in 1997 for the...

February 13, 2018

Feature

Eiger BioPharma has multiple catalysts in orphan diseases in 2018

By Len Zehrs Despite a failed Phase 2 trial in pulmonary arterial hypertension (PAH), Eiger BioPharmaceuticals (NASDAQ:EIGR) still has multiple shots on goal with its targeted therapies for orphan diseases, including a...

February 6, 2018

Category - Feature

Subscribe